HomeAI · summaries
Storia in 3 fonti
Dr Reddy’s launches oral semaglutide in India
Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three tablet strengths for daily use. This launch expands access to advanced diabetes care. Dr Reddys is the second Indian company to introduce oral semaglutide domestically. The company is committed to reliable supply and consistent quality for Indian patients.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Dr Reddy's launches oral semaglutide biosimilar Obeda in India
Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This innovative treatment offers patients the…
- ·
thehindubusinessline.com
Dr Reddy’s launches oral semaglutide biosimilar Obeda
Dr. Reddy’s launches Obeda, an affordable oral semaglutide biosimilar for type 2 diabetes, enhancing treatment options in India.
- ·
Dr Reddy’s launches oral semaglutide in India
Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three tablet strengths for daily use. This…
- ·
thehindu.com
Dr. Reddy’s launches Semaglutide tablets in India
Dr. Reddy’s launches oral semaglutide tablets in India, expanding its GLP-1 therapy portfolio for diabetes treatment.